Search

Displaying results 1381 - 1390 of 6831 in total
  1. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.

  2. Drug

    Hydroxyethyl Starch

    go.drugbank.com/drugs/DB09106
    ApprovedInvestigational

    Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. … HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.

  3. Drug

    Tryptophan

    go.drugbank.com/drugs/DB00150
    ApprovedInvestigationalNutraceuticalWithdrawn

    It can be a precursor to niacin, albeit inefficiently, in mammals.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

  5. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

  6. Target

    Zinc finger and BTB domain-containing protein 7A

    go.drugbank.com/bio_entities/BE0012406
    TargetHumans

    Also directly interacts with transcription factors like SP1 to prevent their binding to DNA (PubMed:12004059). … Collaborates with transcription factors like RELA to modify the accessibility of gene transcription regulatory regions to secondary transcription factors (By similarity).

    Synonyms: Factor that binds to inducer of short transcripts protein 1
  7. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. … [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816]

  8. Drug

    Eteplirsen

    go.drugbank.com/drugs/DB06014
    ApprovedInvestigational

    Eteplirsen directly works on the DMD gene to promote dystrophin production. Eteplirsen was the first treatment for DMD approved by the FDA.[A244925] … is amenable to exon 51 skipping.

  9. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. … [T28] Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia.

  10. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying … [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production.